LLY Revenue
Revenue at Lilly (Eli) rose to $65.2B in fiscal 2025, the highest in the 5 years reported, from $45.0B in 2024.
Total revenues as filed (us-gaap fallback chain; for financials, net revenue or net interest income). Source tag recorded per name.
SOURCE: us-gaap:Revenues · EDGAR CompanyFacts · CIK 59478 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $65.2B | +$20.1B |
| FY2024 | $45.0B | +$10.9B |
| FY2023 | $34.1B | +$5.6B |
| FY2022 | $28.5B | +$223M |
| FY2021 | $28.3B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
◐ PARTLYrevenue growth
The quote contains no checkable figures; the lines it references are shown, and nothing on this page confirms or contradicts it.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYgross margin
The quote contains no checkable figures; the lines it references are shown, and nothing on this page confirms or contradicts it.
FY2025 10-K · FULL RECONCILIATION →✗ RED FLAGInventory vs revenue pace
Inventory grew +36.4pp faster than revenue. Above the 15pp threshold. Management's own account touching these lines appears in the "revenue growth" claim on this page (partial); this page has not independently verified it.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHReceivables pace
Days sales outstanding moved +10.3 days. Carried as watch; this page verifies no stated cause.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Revenue across coverage → · LLY company view →
Net income · Operating cash flow · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.